Meeting
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
T-cell lymphoma secondary to checkpoint inhibitor (CPI) used for other malignancies.
Authors
Kartik Anand
Houston Methodist Cancer Center, Houston, TX
Kartik Anand, Joe Ensor, Shruti Pandita, Sai Ravi Pingali, Shubham Pant, Cassian Yee, Madeleine Duvic, Tej Pandita, Carlos A. Torres-Cabala, Roberto N. Miranda, Youli Zu, Swaminathan Padmanabhan Iyer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Immune-related Adverse Events
Citation
J Clin Oncol 37, 2019 (suppl 8; abstr 88)
DOI
10.1200/JCO.2019.37.8_suppl.88
Abstract #
88
Poster Bd #
E3
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.
First Author: Nathaniel R. Evans
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
A phase II study of talimogene laherparepvec followed by talimogene laherparepvec + nivolumab in refractory T cell and NK cell lymphomas, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and other rare skin tumors (NCI #10057).
First Author: Ann W. Silk
Poster
2023 ASCO Annual Meeting
ENVASARC: A pivotal trial of envafolimab and envafolimab in combination with ipilimumab in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.
First Author: Richard F. Riedel
Poster
2023 ASCO Annual Meeting
Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).
First Author: Aaron Scott Mansfield